Gottwald, Mildred D.
89bio (United States)
6 papers on CoChat
Most cited papers
- Verified
A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus
Alldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., et al. (2001) · New England Journal of Medicine
Epilepsy research and treatmentElectroconvulsive Therapy Studies
Cited by 888
- Verified
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine
Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research
Cited by 522
- Verified
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 280
- Verified
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH
Loomba, R., Amangurbanova, M., Bettencourt, R., Madamba, E., Siddiqi, H., Richards, L., Behling, C., Sirlin, C. B., Gottwald, M. D., Feng, S., et al. (2024) · Gut
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 43
- Verified
Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy
Loomba, R., Daniel, P. C.-Y. N., Amangurbanova, M., Bettencourt, R., Madamba, E., Siddiqi, H., Richards, L., Gottwald, M. D., Feng, S., Margalit, M., et al. (2026) · Hepatology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 17
- Verified
Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., Younes, Z. H., Trotter, J. F., Gunn, N. T., Moussa, S., et al. (2020) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free